Lusutrombopag Medicine 12 June 2018 Extended indication Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures. Therapeutic value No judgement Total cost Registration phase Registration application pending Product Active substance Lusutrombopag Domain Oncology and Hematology Reason of inclusion Main indication Other hematology Extended indication Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures. Current proprietary name Already available biosimilars / generics Proprietary name Mulpleta Manufacturer Shionogi Portfolio holder Mechanism of action Unknown Route of administration Oral Therapeutical formulation Tablet Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Thrombopoietin receptor agonists Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity New medicine ATMP Unknown Submission date February 2018 Expected Registration March 2019 Orphan drug No Registration phase Registration application pending Reimbursement Medicine sluice Additional remarks L-PLUS-2 trail: effective and safe. Met all endpoints. Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Average 7 day / days Frequency of administration 1 times a day Dosage per administration 3 mg References NCT02389621 Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References SPS; NHG-Standaard Virushepatitis en andere leveraandoeningen. Additional remarks De incidentie van cirrose en andere leveraandoeningen in de huisartsenpraktijk is 0,6 per 1000 per jaar en de prevalentie 4,4 per 1000 per jaar. 76% van de cirrosepatiënten heeft thrombocytopenie. Dit betekent dat de totale incidentie 7.752 bedraagt en de prevalentie 56.848. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks